Pneumococcal Vaccines Early and in Combination

• Status: Completed
• Trial end date: 2018-03-15
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether an early schedule of a combination of three doses of PHiD-CV and one dose of PCV13, is superior to three doses of either PCV13 or PHiD-CV.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Menzies School of Health Research
• Treatments: Heptavalent Pneumococcal Conjugate Vaccine; Vaccines

Criteria

Inclusion Criteria:

Indigenous infants

• 4 to 6 weeks of age

• Living in remote communities that have provided signed Expressions of Interest in participating in PREV-IX_COMBO trial

• Intend to remain in their community until their baby is 7 months of age

• Eligible for routine vaccinations.

Exclusion Criteria:

• Prior adverse reaction to pneumococcal conjugate vaccines according to Australian Immunization Handbook.

• Gestational age < 32 weeks